Embody Review
Best for: lowest first-month entry pricing on compounded GLP-1s
Embody (Modern Metabolic Medicine) offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation. Aggressive first-month entry pricing with all 50 states and a 24/7 clinician messaging model led by a board-certified internal medicine CMO.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Embody is one of the most affordable GLP-1 options on the market.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| First month | compounded | $99 |
| First month | compounded | $149 |
| Oral gum | compounded | $329 |
✓ Pros
- •Lowest first-month entry pricing in the compounded segment ($99 first month for semaglutide, $149 for tirzepatide injection)
- •Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- •Available in all 50 states with no insurance friction
- •24/7 unlimited clinician messaging and dose-adjustment support included
- •Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
✗ Cons
- •Refill pricing jumps to $299/month after the first month — initial $99/$149 is an intro rate, not the ongoing cost
- •Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- •Pharmacy partners not publicly named — compounding source transparency is limited
- •Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
Ready to start with Embody?
Starting at $99/month. See current pricing and start your free consultation.
Sources & methodology
Our Embody review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Embody
Alan Meds
Best for: budget-conscious shoppers
Editorial score · methodology
Amazon Pharmacy
Best for: fastest brand-name Foundayo delivery with the cheapest insured price
Editorial score · methodology
AmberHealth
Best for: budget-conscious shoppers
Editorial score · methodology
Frequently Asked Questions
Ready to start with Embody?
Starting at $99/month. See current pricing and start your free consultation.